http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 04 Mar 2026 16:56:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Disc+Medicine%2C+Inc.+++++++For%3A+Mar+02++Filed+by%3A+Savage+William+Jacob/26112314.html si-local-file:///var/storage/secattach/20260304/26112314.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Disc+Medicine%2C+Inc.+++++++For%3A+Mar+02++Filed+by%3A+Savage+William+Jacob/26112314.html Wed, 04 Mar 2026 16:56:00 -0500 IRON O.48149184 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Disc+Medicine%2C+Inc.+++++++For%3A+Mar+02++Filed+by%3A+Savage+William+Jacob/26112314.html si-local-file:///var/storage/secattach/20260304/26112314.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Disc+Medicine%2C+Inc.+++++++For%3A+Mar+02++Filed+by%3A+Savage+William+Jacob/26112314.html Wed, 04 Mar 2026 16:56:00 -0500 IRON O.48149184 http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html <div class="xn-content"> <p><b><i>The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (<span value="ACORN:3119770089" idsrc="xmltag.org" >Boehringer Ingelheim</span>), Lorundrostat (<span value="NASDAQ-NMS:MLYS" idsrc="xmltag.org" >Mineralys Therapeutics</span>), Rilparencel (<span value="NASDAQ-NMS:PROK" idsrc="xmltag.org" >ProKidney</span>), DISC-0974 (<span value="NASDAQ-NMS:IRON" idsrc="xmltag.org" >Disc Medicine</span>), Vonsetamig (<span value="NASDAQ-NMS:REGN" idsrc="xmltag.org" >Regeneron Pharmaceuticals</span>), and others will further boost the market growth.</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Recently published Chronic Kidney http://www.streetinsider.com/Press+Releases/Chronic+Kidney+Disease+Market+Poised+to+Expand+Significantly+During+Forecast+Period+%282025-2034%29+as+Demand+for+Early+Diagnosis+and+Novel+Therapies+Increases+%7C+DelveInsight/26104104.html Tue, 03 Mar 2026 17:31:00 -0500 A.01378694 A.02973684 A.06822034 A.08001773 A.10663646 A.15634349 A.18477764 A.21417454 A.27371291 A.29582908 A.31197700 A.32112375 A.50110045 A.50112548 A.50113944 A.50114033 A.50214844 AMGN IRON JNJ LLY LXRX MAZE MLYS O.00000295 O.00027089 O.00042037 O.00052389 O.00085455 O.00096048 O.00176988 O.00285735 O.00831659 O.01409218 O.01764452 O.02346487 O.03044482 O.05105681 O.07580705 O.10896952 O.11527455 O.13545733 O.15645036 O.20026344 O.26417622 O.31868430 O.48149184 O.49464338 O.50481249 O.70187309 PROK REGN